A Phase I open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies

被引：1
|
作者：
Shah, Nirav N. [1 ]
Krishnan, Amrita Y. [2 ]
Shah, Nina D. [3 ]
Burke, John M. [4 ]
Melear, Jason M. [5 ]
Spira, Alexander I. [6 ]
Kaufman, Jonathan L. [7 ]
Cohen, Jonathon B. [7 ]
Niesvizky, Ruben [8 ]
Popplewell, Leslie L. [2 ]
Chhabra, Saurabh [1 ]
Sharman, Jeff P. [9 ]
Martin, Thomas G. [3 ]
Matheny, Shannon L. [10 ]
Leonard, John P. [8 ]
Molina, Arturo [10 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Rocky Mt Canc Centers, Aurora, CO USA
[5] Texas Oncol, Austin, TX USA
[6] Virginia Canc Specialists, Fairfax, VA USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] New York Presbyterian Hosp, Cornell Campus, New York, NY USA
[9] Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
[10] Sutro Biopharma, San Francisco, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT104
引用
收藏
页数：2
相关论文
共 50 条
  • [31] An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data
    Ogura, Michinori
    Hatake, Kiyohiko
    Davies, Andrew
    Crump, Michael
    Tobinai, Kensei
    Smith, Mitchell R.
    Offner, Fritz
    Wang, Shaw-Ling
    Ishibashi, Taro
    Paccagnella, Luisa
    Vandendries, Erik
    MacDonald, David A.
    BLOOD, 2012, 120 (21)
  • [32] Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
    Lin, Chia-Chi
    Yang, Tsai-Sheng
    Yen, Chia-Jui
    Cheng, Rebecca
    Liu, Junjun
    Hsu, Chiun
    ONCOLOGIST, 2020, 25 (12): : E1921 - E1929
  • [33] A phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies.
    Infante, Jeffrey R.
    Goel, Sanjay
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Robbins, Paul B.
    D'Angelo, Gina
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] AN OPEN-LABEL PHASE I DOSE-ESCALATION CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC PROFILE AND PRELIMINARY EFFICACY OF VG161 IN PATIENTS WITH ADVANCED PRIMARY LIVER CANCER
    Shen, Yinan
    Shi, Guoming
    Liang, Xingmei
    Jin, Xinyan
    Wang, Youlei
    Wei, Guyue
    Chen, Yi
    Huang, Xiaoyong
    Lu, Jiacheng
    Xia, Huiqun
    Xiao, Miao
    Rahimian, Shah
    Zhao, Ronghua
    Li, Yuwei
    Lin, Danni
    Fang, Tian
    Chen, Wei
    Ma, Tao
    Bai, Xueli
    Liang, Tingbo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A725 - A725
  • [35] Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
    Stathis, Anastasios
    Maddocks, Kami J.
    Flinn, Ian
    Mejia, Alex
    Palomba, Maria Lia
    Zildjian, Sybil
    Murphy, Mary
    Deckert, Jutta
    Ruiz-Soto, Rodrigo
    Freedman, Arnold
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma
    Raje, Noopur
    Richardson, Paul
    Hari, Parameswaran N.
    Mahindra, Anuj
    Kaster, Sarah
    Connolly, Christine
    Rivera, Linda
    Chetri, Gaurav
    Dean, Sarah
    Jacobs, Paulette
    Saad, Ayman
    Laubach, Jacob
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Adams, Jennifer
    Makrides, Wendy
    Weller, Edie
    Munshi, Nikhil
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 1483 - 1483
  • [37] An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).
    Hillmen, Peter
    Gribben, John G.
    Follows, George A.
    Milligan, Donald W.
    Sayala, Hazem A.
    Moreton, Paul
    Oscier, David
    Dearden, Claire E.
    Kennedy, Daniel B.
    Pettitt, Andrew R.
    Nathwani, Amit
    Cohen, Dena
    Gregory, Walter M.
    Rawstron, Andy C.
    Hayward, Colin R. W.
    Pocock, Christopher
    BLOOD, 2009, 114 (22) : 1331 - 1332
  • [38] Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study
    Wang, Xicheng
    Zhou, Jianfeng
    Li, Yan
    Ge, Yuping
    Zhou, Yanping
    Bai, Chunmei
    Shen, Lin
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2020, 12 : 21 - 33
  • [39] A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
    Gumbleton, Matthew
    Allan, Stephanie
    Conway, Hannah
    Boucher, Kenneth
    Marvin, James
    Hawks, Josiah
    Burnett, William
    Van Brocklin, Matthew
    Whisenant, Jonathan
    Gilcrease, Glynn
    Gupta, Sumati
    BMC RESEARCH NOTES, 2023, 16 (01)
  • [40] Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.
    Gutierrez, Martin
    Subbiah, Vivek
    Nemunaitis, John J.
    Mettu, Niharika B.
    Papadopoulos, Kyriakos P.
    Barve, Minal A.
    Feliz, Luis
    Lihou, Christine Francis
    Tian, Chenwei
    Ji, Tao
    Silverman, Ian M.
    Chugh, Rashmi
    Saleh, Mansoor N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345